Countdown to IPBC Korea 2023
Just one month until IP leaders will gather in Seoul for an agenda tackling policy developments, market trends, and commercial pressures
Just one month until IP leaders will gather in Seoul for an agenda tackling policy developments, market trends, and commercial pressures
Opinion: Popular attacks on America’s life sciences patent system are highly misleading
Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112
The vaccine maker has paid for use of state-owned IP, but several points of contention remain
28 February 2023
The region is lagging behind its global peers in invention productivity but there are ways this gulf can be crossed
24 February 2023
In the second part of IAM’s exclusive interview with USPTO Director Kathi Vidal, she shares her thoughts on international patent issues
23 February 2023
While the litigation system is attracting most of the attention, the new right has the potential to be more valuable than anything granted anywhere else in the world
23 February 2023
In the first of a two-part interview with IAM, the USPTO director opened up about the most pressing issues facing the US patent system
22 February 2023
Joerg Thomaier also shares his thoughts on the UPC and EPO patent quality in an exclusive IAM interview
22 February 2023
A 15% boost could help bolster staffing and shorten timelines but smarter use of funds is essential
20 February 2023
It’s a win for the patent owner seeking to reveal who is behind the IPR petitioner, and may deliver estoppel benefits in underlying district court litigation
17 February 2023
Germany ratifies agreement, Sunrise Period to start on 1 March
17 February 2023
IAM’s latest panel report surveyed sentiment of senior in-house and private practice patent professionals across a range of topics
16 February 2023
Unlock unlimited access to all IAM content